From Big Pharmas like Novartis and Gilead to liver specialists and one-asset biotechs, it seems like everyone in biopharma has some skin in the NASH game.   It makes sense, said Tarek Hassanein, M.D., a professor of medicine and director of outreach services for liver transplantation at the Univers…